Global GLP-1 receptor agonist market is estimated to witness high growth, owing to increasing prevalence of obesity and rising diabetes population
Global GLP-1 receptor agonist market is estimated to be valued at USD 25.10 Bn in, exhibiting a CAGR of 12.1% over the forecast period 2024-2031. The market growth is driven by rising prevalence of obesity and diabetes across the globe. Furthermore, growing awareness and availability of new treatment options can drive the market growth.
Market Dynamics:
Global GLP-1 receptor agonist market growth is driven by increasing prevalence of obesity and diabetes. Obesity has emerged as a major public health problem worldwide with over 650 million adults are clinically obese. Moreover, the number of people with diabetes had increased from 108 million in 1980 to 422 million in 2014. GLP-1 receptor agonists are effective anti-diabetic drugs for management of type 2 diabetes.
Rising approval and launch of new drugs in the market can drive the market growth. For instance, in 2021, Wegovy(semaglutide) was approved for chronic weight management. It is the first drug approved by USFDA for long term weight loss management. tirzepatide was approved in early 2022 which is a dual GIP and GLP-1 receptor agonist demonstrating superior efficacy over other monotherapy.
Increasing prevalence of diabetes can drive the market growth
Global GLP-1 receptor agonist market growth is driven by rising prevalence of diabetes across the globe. As per the International Diabetes Federation, approximately 463 million adults aged between 20-79 years lived with diabetes in 2019 and this number is expected to rise to 700 million by 2045. GLP-1 receptor agonists are an effective treatment option for type 2 diabetes as these help control blood sugar levels and promote weight loss. Growing diabetic population can boost demand for advanced diabetes management drugs like GLP-1 receptor agonists.
Advancements in GLP-1 analog technology Continuous technological advancements in GLP-1 receptor agonist drugs can drive the market growth. Pharmaceutical companies are focusing on developing more potent and long-acting GLP-1 analogs with improved efficacy and safety profiles. For instance, drugs with half-lives of 7 days or monthly injections are being researched which will provide better compliance over existing daily injectables. Product line extensions of top-selling brands with new formulations. The commercial success of such innovative drug variants is positively impacting the overall GLP-1 receptor agonist industry.
High cost of GLP-1 drugs restricting adoption
GLP-1 receptor agonist market growth can be hampered by high cost of these medications. On an average, the annual cost of GLP-1 therapy ranges from USD 3,000-5,000 in the US which is unaffordable for many patients. This is a major roadblock, especially in developing nations with large diabetic populations but limited healthcare budgets. The high prices force patients to opt for generic alternatives or forego treatment altogether. Healthcare systems have to incur massive costs to include such premium drugs under insurance coverage.
Safety concerns limiting clinical use
Tolerability issues associated with GLP-1 agonists can hamper the market growth. Common side effects reported are nausea, vomiting and diarrhea which may discourage patients from continuing treatment. Rare but serious risks like pancreatitis and thyroid cancer have also been linked to certain GLP-1 drugs. This warrants cautious clinical use, especially in high-risk groups. The requirement of subcutaneous injections impart a negative impact on patient compliance over oral medications. Growing safety scrutiny by regulators on new drug approvals further delays market entry of novel variants.
Expansion into new therapeutic areas
As GLP-1 agonists show benefits beyond glycemic control in weight loss and cardiovascular risk reduction, there will be lucrative opportunity to tap new clinical indications. Many companies are conducting trials to evaluate the role of these drugs in non-alcoholic steatohepatitis, obesity and neurological disorders. Successful outcomes may help GLP-1 receptor agonists carve out a wider market scope beyond diabetes alone.
Advancements in alternative delivery systems
Emerging innovations in delivery forms like oral, nasal and inhaled preparations can provide huge market potential as compared to existing subcutaneous injections. Oral semaglutide was the first non-injectable GLP-1 approved by USFDA in 2021 which can address major patient compliance barriers. Other innovations in the pipeline include patches, pills and pulmonary delivery devices. Once commercialized, these novel administration routes can facilitate broader accessibility and uptake of GLP-1 therapy.
Link: https://www.coherentmarketinsights.com/market-insight/glp-1-receptor-agonist-market-4632
Key Development
- On July 11, 2024, Pfizer Inc., a global pharmaceutical company, announced the selection of its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, based on ongoing pharmacokinetic study results (NCT06153758). In the second half of 2024, Pfizer Inc. plans to initiate dose optimization studies to evaluate various doses of this formulation, aiming to inform registration enabling studies.
- In February 2024, Eli Lilly and Company, a pharmaceutical company, announced its plan to introduce Mounjaro, a successful medication for diabetes and obesity, into the Indian market. In January 2024, Novo Nordisk A/S, a pharmaceutical company, announced research collaborations with two U.S. biotech companies as part of its strategy to lead in the development of new therapies for cardiometabolic disorders ahead of larger pharmaceutical firms
- In March 2023, the NHS approved Wegovy, a semaglutide injection for weight loss that mimics the hormone GLP-1 to suppress appetite. This approval will make Wegovy available to thousands of people with obesity in England, U.K.
- In November 2021, Novo Nordisk A/S and Dicerna Pharmaceuticals, Inc. entered into a partnership to co-develop and commercialize RNA interference therapies targeting liver-related cardiometabolic diseases such as Non-Alcoholic Steatohepatitis (NASH) and type 2 diabetes
Key Players: Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca, Perrigo Company PLC, 3M Company, Bausch Health, Taro Pharmaceutical Industries, Novan Inc., Serum Institute of India Pvt. Ltd., Orgenesis biotech company, Verrica Pharmaceuticals, AbbVie Inc., Lee's Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals
